 {#Sec1}

The study has shown quality and reach can be successfully achieved in a practice-led scale-up process of a complex intervention outside of a controlled study.We found RE-AIM a useful framework for investigating scale-up, and we describe how it was operationalised within a pragmatic evaluation.The findings provide empirical evidence of the challenges of developing and embedding systems to monitor and evaluate practice-led scale-up in the 'real world' that are rigorous *and* pragmatic.

Background {#Sec2}
==========

Scaling-up and sustaining evidence-based health interventions is essential to achieve widespread improvements in the quality of care \[[@CR1], [@CR2]\]. However, we have a poor understanding of how effective complex healthcare interventions transition from a trial to being implemented at scale-up and sustained in real-world settings \[[@CR3]--[@CR10]\]. Scale-up needs to be supported by effective monitoring and evaluation systems \[[@CR4], [@CR11], [@CR12]\], but there are challenges in balancing adequately rigorous systems to monitor and evaluate scale-up with the need for proportionate and pragmatic approaches \[[@CR12], [@CR13]\].

Worldwide, osteoarthritis (OA) is one of the most prevalent causes of pain and disability, and an estimated 6.83 million people consult for knee or hip OA in the UK \[[@CR14], [@CR15]\]. Yet current management is largely sub-optimal, and the burden on individuals and society remains high \[[@CR16]--[@CR18]\]. Although rehabilitation professionals (such as physical and occupational therapists) understand the need to implement evidenced-based interventions, their ability to implement new knowledge into clinical practice remains limited \[[@CR19]--[@CR21]\]. ESCAPE-pain is a complex evidence-based intervention (EBI) for people with knee or hip OA that combines structured education and self-management strategies with an individualised exercise regime in line with clinical guidelines \[[@CR22]\]. Due to the evidence demonstrating ESCAPE-pain's clinical and cost effectiveness \[[@CR23]--[@CR26]\], the programme was adopted by England's 15 Academic Health Science Networks (AHSNs) as a priority for scale-up nationally.

The study aimed to evaluate the scale-up of ESCAPE-pain as a complex EBI by a network of AHSNs in England. Tied to this, we discuss the role of pragmatic data collection and monitoring in efforts to scale EBIs within real-world settings.

Methods {#Sec3}
=======

Study design {#Sec4}
------------

This is a pragmatic evaluation of the scale-up of ESCAPE-pain using the RE-AIM framework \[[@CR27], [@CR28]\]. By pragmatic, we refer to an approach that is based in practice (rather than taking a research or theoretical perspective) using routine monitoring data collected as part of an AHSNs' national programme from April 2014 to December 2018. Table [1](#Tab1){ref-type="table"} outlines how the RE-AIM framework has been applied within the study to measure Reach, Effectiveness, Adoption, Implementation and Maintenance. Table 1Mapping the RE-AIM framework to the studyDomainDescription of domain and outcome metricOutcome measure(s) usedReachIndividual level measure of participation.Number of participants and joint affected.EffectivenessParticipants' outcome or benefits received.KOOS/HOOS\^ measuring levels of pain, activities of daily living and quality of life.AdoptionSetting/location programme was adopted.Type of setting, provider and professional delivering the programme.ImplementationFactors related to the implementation of the programme.Number of trained facilitators, facilitator feedback on programme implementation and delivery, self-reported compliance with core components, participant adherenceMaintenanceWhether the programme is maintained (or sustained) post implementation.Number of sites delivering ESCAPE-pain post-implementation\^Knee/Hip Injury and Osteoarthritis Outcome Score

ESCAPE-pain programme {#Sec5}
---------------------

ESCAPE-pain is an EBI integrating education and exercise for people with chronic knee and/or hip pain and OA, which promotes self-management to improve quality of life and function \[[@CR23]--[@CR26]\]. People attend in groups of 10--12 people, twice a week, over 6 weeks (12 sessions). Each session is led by a trained facilitator and comprises 20--25 min of structured education about OA and self-management strategies, and 30--45 min of exercise. Details of the programme are available at <http://www.escape-pain.org/>. ESCAPE-pain is underpinned by a randomised controlled trial and economic evaluation \[[@CR23]--[@CR26]\].

Scaling-up ESCAPE-pain {#Sec6}
----------------------

NHS England established 15 Academic Health Science Networks (AHSNs) to help accelerate the spread and adoption on innovation in healthcare. In 2014, ESCAPE-pain was selected by the AHSN for south London (Health Innovation Network) as a priority for local scale-up and was resourced by a small team (i.e. 2--3 project managers and administrative support) led by a clinical and programme director. In April 2018, ESCAPE-pain became a national programme for scale-up supported by all 15 AHSNs across England for a 2-year period. Scale-up was coordinated by a national programme manager and dedicated resource (e.g. project manager, clinical champion) within each AHSN to support local scale-up.

ESCAPE-pain training course {#Sec7}
---------------------------

A 1-day training course was developed to support the scale-up of ESCAPE-pain to help ensure fidelity to the core component of the programme and quality. The course is mandatory for anyone delivering ESCAPE-pain. Participants learn about the evidence-base and ethos underpinning ESCAPE-pain, develop a detailed understanding of the programme's format, and gain skills and knowledge to support the implementation and delivery of the programme.

Data collection {#Sec8}
---------------

The AHSNs collect routine data to monitor the scale-up of ESCAPE-pain, which were used to measure outcomes for each domains of the RE-AIM framework. AHSNs receive no participant identifiable data, i.e. providers anonymise all data prior to submitting it.

Reach---The number of participants attending each cohort of ESCAPE-pain and the joint affected (i.e. hip or knee OA). Demographic data are not collected. There are no local prevalence data for hip and knee OA available at the level of individual sites to be able to determine a reliable denominator. Nationally, there are an estimated 4.11 million cases of knee OA and 2.46 million cases of hip OA \[[@CR29]\].

Effectiveness---Pre-/post-programme clinical outcomes for participants measured using the Knee/Hip Injury and Osteoarthritis Outcome Score (KOOS and HOOS) sub-scales of pain, activities of daily living (ADL) and quality of life (QoL) \[[@CR30], [@CR31]\].

Adoption---The number of sites and the type of setting (e.g. clinical outpatients, non-clinical community), provider organisation (e.g. NHS, local authority/council, charity, leisure/fitness centre) and professional (e.g. physiotherapist, therapy assistant or fitness instructor) delivering ESCAPE-pain.

Implementation---Self-reported compliance with the core components of ESCAPE-pain, namely (i) a 1-h session twice a week for 6 weeks (i.e. 12 sessions), (ii) each session contains exercise and structured education, (iii) the programme follows a cohort structure and (iv) the programme must be delivered by a trained facilitator. Facilitators' self-reported levels of understand of the programme and ability to implement and deliver the programme via a routine post-training questionnaire. Participant adherence measured by the number of people completing the programme. Completion was defined as participants attending 75% of sessions, to match the level of adherence within the clinical trial \[[@CR23], [@CR24], [@CR26]\].

Maintenance---The number of sites continuing or ceasing to deliver ESCAPE-pain at \< 1 year, 1--2 years and \< 2 years post-implementation. It is not possible to report on maintenance at an individual level because long-term follow-up data for clinical outcomes are not collected.

Data analysis {#Sec9}
-------------

Clinical outcome data were available for 3664 people with knee OA from 72 sites and 209 people with hip OA from 33 sites. Only participants with pre- *and* post-outcome data were included in the analysis. Data from all sites were analysed as a single dataset. Paired *t* test was used to determine the mean difference for each subscale, and effect size was calculated using Cohen's D. Data were analysed using R v3.5.1. Data are presented as mean change in KOOS or HOOS points (confidence intervals, CI), where an increase in scores indicates an improvement. All other data were analysed using descriptive statistics.

Results {#Sec10}
=======

Reach {#Sec11}
-----

Nine thousand one hundred fifty people with hip and knee OA have participated in the ESCAPE-pain programme between April 2014 and December 2018 (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Cumulative number of participants completing and number of sites delivering ESCAPE-pain

Effectiveness {#Sec12}
-------------

Pre- and post-rehabilitation data were only available from 3614 people with knee and 209 people with hip pain who completed the ESCAPE-pain programme (i.e. defined as attending ≥ 75% of sessions) (Table [2](#Tab2){ref-type="table"}). Participants saw improvements in pain by 7.6 (CI 7.2, 8.1) KOOS points and 5.2 (CI 3.4, 7) HOOS points, function 8.2 (7.7, 8.7) KOOS and 5.5 (3.5, 7.5) HOOS, and quality of life 8.1 (7.5, 8.6) KOOS and 5.6 (3.3, 7.9) HOOS (Table [2](#Tab2){ref-type="table"}). The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function score was used as the primary outcome for the ESCAPE-pain clinical trial \[[@CR24]\]. It is possible to calculate the WOMAC function score from the KOOS \[[@CR31]\]. WOMAC function score showed an improvement of − 5.49 (95% CI − 7.78, − 3.19, *n* = 278) in the original trial \[[@CR24]\], compared to − 5.38 (− 5.69, − 5.06, *n* = 3590) in this study. Table 2Effectiveness of ESCAPE-pain programme for knee and hip OASample size\^Pre-mean (SD)Post-mean (SD)Mean change (95% CI change)Effect size (Cohen's D)KOOS Domain Pain361448.9 (17.3)56.5 (18.5)7.6 (7.2, 8.1)\*\*0.5 Function (ADLs)359053.0 (19.2)61.1 (20.0)8.2 (7.7, 8.7)\*\*0.6 Quality of life357134.0 (18.8)42.1 (19.8)8.1 (7.5, 8.6)\*\*0.5HOOS Domain Pain20949.5 (18.4)54.7(20.5)5.2 (3.4, 7.0)\*\*0.4 Function (ADLs)20553.7 (20.2)59.2 (20.8)5.5 (3.5, 7.5)\*\*0.4 Quality of life20339.7 (21.1)45.2 (20.5)5.6 (3.3, 7.9)\*\*0.3*KOOS/HOOS* Knee/Hip Injury and Osteoarthritis Outcome Score, *ADLs* activities of daily living, *SD* standard deviation, *CI* confidence interval\^Number of participants with complete datasets (i.e. all sections of the KOOS/HOOS completed before and after completing the programme) out of a total of 9150 people completing the programme\*\**p* \< 0.001

Adoption {#Sec13}
--------

Between September 2014 and December 2018, 116 sites were delivering ESCAPE-pain, of which 81 were hospital outpatient departments and 35 in non-clinical community settings (Fig. [1](#Fig1){ref-type="fig"}). Following the adoption of ESCAPE-pain as an AHSN national programme in April 2018, there were almost twice the number of sites by December 2018. Compared to the original model of delivery tested within the clinical trial (i.e. physiotherapists within outpatient departments), the programme has been adopted across an increasing range of settings, providers, and profession (Table [3](#Tab3){ref-type="table"}). However, physiotherapists delivering ESCAPE-pain in outpatient departments remain the dominant model (i.e. 70% or 81/116 sites). A comparison of effectiveness by setting type (i.e. clinical versus non-clinical) showed no significant different in outcomes (Table [4](#Tab4){ref-type="table"}), although a smaller dataset was available for non-clinical settings. Table 3Range of settings, providers and practitioners that have delivered ESCAPE-painSettingProviderProfessionalPhysiotherapy dept.NHS (public health provider)PhysiotherapistLeisure/fitness centreNHS (public health provider)Therapy assistant and/or physiotherapistLeisure/fitness centreLeisure/fitness providerPhysiotherapist and/or fitness instructorWorkplaceNHS occupational healthPhysiotherapistCommunity centreThird sectorPhysiotherapist or fitness instructorCommunity centreLocal authority/town councilPhysiotherapist and/or fitness instructorTable 4Effectiveness of ESCAPE-pain programme for knee and hip OA by setting typeClinical settingNon-clinical settingSample size\^Mean change† (95% CI change)Sample size\^Mean change† (95% CI change)KOOS domain Pain32197.68 (6.91, 7.93)3957.33 (5.86, 8.80) Function (ADLs)31968.24 (7.35, 8.35)3947.74 (6.33, 9.14) Quality of life31778.11 (7.21,8.39)3947.66 (6.02, 9.31)HOOS domain Pain1435.40 (3.37, 7.03)664.77 (1.14, 8.40) Function (ADLs)1406.05 (3.53, 7.46)654.30 (0.77, 7.83) Quality of life1396.04 (3.31, 7.87)644.62 (0.35, 8.90)*KOOS/HOOS* Knee/Hip Injury and Osteoarthritis Outcome Score, *ADLs* activities of daily living, *CI* confidence interval\^Number of participants with complete datasets (i.e. all sections of the KOOS/HOOS completed before and after completing the programme) out of a total of 9150 people completing the programme†Between-group difference (clinical/non-clinical) for all domains of the HOOS/KOOS was not significant (\> 0.05)

Implementation {#Sec14}
--------------

Adherence data were available for 6072 participants; 78.5% (*n* = 4767) of participants completed 75% of sessions. Seven hundred seventy people (or facilitators) have been trained to deliver ESCAPE-pain (488 physiotherapists, 282 fitness instructors). Facilitators (*n* = 665) agreed (13%) or strongly agreed (87%) they understood what ESCAPE-pain was and how to implement it, 29% agreed and 71% strongly agreed they felt able to deliver ESCAPE-pain. All sites self-report compliance against the programme's core 4 components when implementing ESCAPE-pain.

Maintenance {#Sec15}
-----------

As of December 2018, 84.1% of sites continue to deliver ESCAPE-pain post-implementation (116 out of a total of 138 sites). Table [5](#Tab5){ref-type="table"} shows the number of sites delivering/ceasing ESCAPE-pain after the programme was implemented by three time categories (i.e. \< 1, 1--2 and \> 2 years). Of all the sites that have implemented ESCAPE-pain (*n* = 138), it was stopped after less than 1 year by 11 (8%) sites. Of those sites delivering ESCAPE-pain at December 2018 (*n* = 116), it has been delivered for more than 2 years by 24 (20.7%) sites. Table 5Number of sites delivering/ceasing ESCAPE-pain post-implementationTime since implementation (years)\*Number of sites delivering ESCAPE-painNumber of sites ceasing ESCAPE-pain\< 182111--2109\> 2242\*Based on the time the programme began being delivered at a site

Discussion {#Sec16}
==========

The widespread implementation of healthcare innovations usually takes many years; many initiatives fail \[[@CR3]\] or are not translated into practice \[[@CR32]\]. We used RE-AIM to evaluate the national scale-up of ESCAPE-pain, a complex healthcare intervention for knee and hip OA, by England's 15 Academic Health Science Networks (AHSNs).

Since 2014, ESCAPE-pain has been adopted in over 110 sites, reaching over 9000 people with knee or hip OA. Whilst this is promising, national prevalence data for knee (4.11 million) and hip (2.46 million) OA in England indicate a need for continuing to expand reach \[[@CR29]\]. Although it is delivered predominately by physiotherapists, a growing number of exercise professionals are now delivering the programme. It has been adopted across an expanding range of settings beyond the original model tested in the trial (from NHS outpatient departments to non-clinical community venues), and by a diverse number of providers and funding arrangements. This shows that complex healthcare interventions of this kind can be scaled-up successfully into similar types of settings and professions and 'spread-out' into different contexts \[[@CR3], [@CR5]\].

Monitoring demonstrates that ESCAPE-pain has been scaled-up; however, it is important to determine what (exactly) has been implemented (i.e. fidelity) and whether it is effective (i.e. delivering intended outcomes) \[[@CR33], [@CR34]\]. Measuring intervention fidelity and quality within a national scale-up process has been pragmatic in its approach. A mandatory 1-day training course was developed as a strategy to help safeguard that ESCAPE-pain was implemented with fidelity (i.e. by building knowledge and skills to implement and deliver the programme) \[[@CR35]\]. In addition, all sites implementing ESCAPE-pain were required to self-report compliance with the programme's core components---sites that do not report compliance are not considered to be delivering ESCAPE-pain. Participants' adherence levels were comparable with those observed within the original trial where 55% of participants completed 10 or more sessions in the ESCAPE-pain group intervention \[[@CR23], [@CR24]\].

Individual level long-term follow-up data are not collected as part of the AHSNs' national programme, which means that it is not possible to determine if the self-management strategies and subsequent benefits delivered by ESCAPE-pain are maintained by participants. At an organisational level, the number of sites continuing to deliver the programme is high, suggesting it is largely sustained in practice settings once implemented. There is debate in the literature about what constitutes sustainability (e.g. continued delivery of intervention components, extent of integration, realisation of outcomes, duration) \[[@CR8], [@CR34]\]. In the case of ESCAPE-pain, the majority of sites are \< 1-year post-implementation; therefore, the extent of long-term sustainability is to be seen.

As interventions move from highly resourced, controlled research conditions into 'real-world' settings, there is a risk effectiveness can be reduced due to the intervention's essential core components being incorrectly implemented \[[@CR34], [@CR36]\]. Therefore, it is important to continue to monitor the effectiveness of interventions as they are implemented in different contexts \[[@CR12], [@CR13], [@CR34]\]. Critically for ESCAPE-pain, on-going data collection demonstrated that the programme's effectiveness has been maintained as it spread from a controlled \[[@CR24]\], cloistered trial setting, into very different 'real-world' clinical and community settings. However, interpretation of effectiveness needs to recognise the potential impact of missing data as people with poorer outcomes may be underrepresented.

The systematic, on-going monitoring of scale-up demonstrated by AHSNs for ESCAPE-pain is uncommon \[[@CR12], [@CR13], [@CR34], [@CR37]\], despite calls to evaluate the widespread implementation of self-management programmes for OA, like ESCAPE-pain \[[@CR37]\]. However, data collection has been difficult as staff (both clinical and non-clinical) in sites often lack systems to routinely collect data, have little time and may be unable or reluctant to collect data. Although the AHSNs have created systems to ease the burden of collecting and analysing data, there is no way of enforcing data return. Consequently, data return is sporadic. All sites have returned data, but not all sites return data all the time (i.e. as requested quarterly), and the sites returning data vary overtime. In addition, the completeness of data returned varies. This results in limitations for reporting scale-up.

Other limitations are that implementation outcomes relied on self-reported and indirect measures (e.g. compliance with core components of ESCAPE-pain, numbers trained, facilitators' ability implement and deliver ESCAPE-pain). However, impartial observation of implementation across a large number of geographically dispersed sites was not feasible. Whilst these measures do not guarantee the programme was implemented and delivered with fidelity or quality, they provided a pragmatic approach to monitoring. A further challenge going forward is that as the number of sites expands it is essential that systems and processes underpinning monitoring (e.g. data collection, quality controls, analysis and reporting) continue to be rigorous and sustainable (i.e. feasibly resourced) \[[@CR12], [@CR13]\].

Conclusions {#Sec17}
===========

An evidence-based complex intervention can be implemented at scale successfully: achieving reach *and* maintaining quality. Importantly, ESCAPE-pain's clinical effectiveness has been sustained as it has transitioned into a diverse range of 'real-world' settings, beyond those tested in the original trial. However, scale-up has been a gradual process requiring on-going, dedicated resources over 5 years by a national network of AHSNs.

Whilst the collection of data for monitoring and evaluation is critical in understanding implementation and scale-up, there are significant challenges in developing systems sufficiently rigorous, proportionate and locally acceptable.

ADL

:   Activities of daily living

AHSN

:   Academic Health Science Network

EBI

:   Evidence-based intervention
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:   Enabling Self-management and Coping with Arthritic Pain using Exercise

HOOS

:   Hip Injury and Osteoarthritis Score

KOOS

:   Knee Injury and Osteoarthritis Score

OA

:   Osteoarthritis

QOL

:   Quality of life

RE-AIM

:   Reach, Effectiveness, Adoption, Implementation and Maintenance
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